Skip to main content

Table 1 Baseline Characteristics in each treatment group

From: Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial

Variables n = 36Group 1
n = 18
Group 2
n = 18
P-Value
Mean ± SDMean ± SD
Age (Years)47.22 ± 14.1753.89 ± 14.110.17
Duration of Known Hepatitis C (Years)4.61 ± 3.843.55 ± 1.920.31
Duration of Dialysis (Years)4.23 ± 2.635.33 ± 2.790.23
HCV RNA PCR (log 10 IU/ml)5.88 ± 6.06.16 ± 6.580.46
GenderMaleN = 11N = 11___
FemaleN = 7N = 7
Genotype 1 PatientsN = 06N = 06___
Genotype 2 PatientsN = 00N = 01___
Genotype 3 PatientsN = 12N = 11___
CirrhosisN = 04N = 06___
Treatment ExperiencedN = 03N = 02___
Treatment WithdrawalN = 03N = 01___
Aspartate Aminotransferase
(U/L)
57.06 ± 48.7134.5 ± 25.270.09
Alanine Aminotransferase
(U/L)
50.89 ± 44.0840.50 ± 34.860.44
Hemoglobin
(g/dl)
10.53 ± 1.6111.51 ± 1.150.04
White Blood Cells
× 103/mm3
6.33 ± 1.936.44 ± 1.910.87
Platelets
×103/mm3
163.27 ± 65.34175.44 ± 40.110.51
Independent t-test was used to assess the significance